Healthcare | January 28, 2025
Mankind Pharma launches 45-day healthcare mission at Mahakumbh
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
PAT after MI is Rs. 41 crore which is 162% increase
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Subscribe To Our Newsletter & Stay Updated
